20 Aug 2016

NZ lagging in melanoma drug funding - study

7:12 pm on 20 August 2016

New Zealand is still far behind Australia and the United Kingdom when it comes to funding of melanoma drugs, according to a new study.

A bright  yellow and aqua sphere, representing the immune system, sits alongside a brown cancer sphere with little goemetric shapes between indicating the drug's action

Manufacturer's illustration of how the new melanoma drug, Keytruda, stops cancer cells hiding from the immune system Photo: Supplied

Earlier this month, Pharmac announced it would fully fund Keytruda from 1 September.

But last week, a woman with stage-four melanoma told the Health Select Committee Pharmac could have saved hundreds of lives if it had moved faster to fund Keytruda and Opdivo.

The paper - published by the Medical Journal - said although more funding was now available, the way the funding decisions were made was still a problem.

One of its authors, Rosalie Stephens, a Melanoma New Zealand trustee, said there had been so much suffering and death, because of the time it took for basic drugs to be subsidised.

Get the new RNZ app

for ad-free news and current affairs